Alligator Bioscience AB reports financial results for Q1 2025 and provides a business update
24-month data from OPTIMIZE-1 show 29.4% survival rate for mitazalimab—three times higher than chemotherapy alone FDA alignment secure ...
Alligator Bioscience AB reports financial results for Q1 2024 and provides a business update
Mitazalimab Phase 3 preparations underway following positive top-line results from OPTIMIZE-1 Phase 2 study in pancreatic cancer Positive in ...
Alligator Bioscience AB reports financial results for Q1 2023 and provides a business update
Mitazalimab OPTIMIZE-1 Phase 2 trial in pancreatic cancer completes enrolment following positive interim results; top-line data due Q1 2024 ...
Alligator Bioscience AB: Interim report January–March 2022
A Quarter of Advancements for Alligator’s Key Assets “Q1 2022 was marked by many important advancements. We made progress with our key ass ...
Alligator Bioscience AB: Interim report January–March 2021
High activity during the first quarter ”So far, 2021 has been characterized by high activity, with a research collaboration that validates o ...
Alligator Bioscience AB (publ) Interim report January-March 2020
Stronger focus on clinical projects "The focusing of our operations protects the company’s liquidity, but is also part of our long-term ...
Alligator Bioscience AB (publ) Interim report January-March 2019
First patient dosed in Phase I clinical study of ATOR-1015 Significant events January-March• First patient dosed in Phase I clinical study o ...
Alligator Bioscience AB Interim Report January-March 2018
Positive preclinical data for ATOR-1015 "Data provide strong support for our claims that ATOR-1015 is a next generation bispecific CTLA- ...
Alligator Bioscience AB Interim report January-March 2017
Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) today announced its report for the first quarter 2017. “In the first quarte ...